ClinicalTrials.gg
CompletedNCT06829225Updated Feb 17, 2025

Single Dose Study of Tulisokibart (MK-7240) in Healthy Chinese Participants (MK-7240-002)

A Phase 1 interventional study of Tulisokibart and Placebo in Colitis, Ulcerative, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-17.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Nov 2024, 2 years ago, and no results have been posted to the registry.
  • Registered 7 months after the study started (first participant enrolled Jun 2024, registered Feb 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Colitis, Ulcerative by Merck & Co., Inc — 2 open to participants now, 3 under way, 2 of them phase 3. Colitis, Ulcerative · Merck & Co., Inc.

Enrollment
9th of 11
48 · median 100
Started
2024
with 1 other
Phase 1
2 of 13
none open now
Registered
12th of 13
by date

Among the 13 studies in Colitis, Ulcerative by Merck & Co., Inc, this one is the 9th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2024, is one of 2 in phase 1, and was the 12th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

2 of the 13 studies in Colitis, Ulcerative by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Colitis, Ulcerative by Merck & Co., Inc, or all of them as a file.
02

Study summary

The goal of this study is to learn about the safety of tulisokibart in healthy participants and what happens to tulisokibart over time when participants receive treatment intravenously versus subcutaneously.

03

Conditions studied

  • Colitis, Ulcerative

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Inclusion Criteria include, but are not limited to:

  • Be in good health
  • Has a (BMI) ≥18 and ≤28 kg/m\^2 and weight ≥40.0 kg
  • Continuous non-smoker who has not used tobacco or nicotine-containing products for at least 3 months prior to the dosing of study drug

Exclusion criteria

Exclusion Criteria:

Exclusion Criteria include, but are not limited to:

  • History of cancer ()
  • Has positive serum test for (HIV), or virus infection
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Tulisokibart Dose 1 Treatment Subcutaneous (SC) Injection

    Participants will receive a single SC injection dose of tulisokibart at dose 1 on Day 1.

    Drug: Tulisokibart

  • Placebo comparator
    Placebo SC Injection

    Participants will receive a single SC injection dose of placebo at on Day 1.

    Drug: Placebo

  • Experimental
    Tulisokibart Dose 1 Intravenous (IV) Infusion

    Participants will receive a single IV infusion dose of tulisokibart at dose 1 on Day 1.

    Drug: Tulisokibart

  • Experimental
    Tulisokibart Dose 2 IV Infusion

    Participants will receive a single IV infusion dose of tulisokibart at dose 2 on Day 1.

    Drug: Tulisokibart

  • Experimental
    Tulisokibart Dose 3 IV Infusion

    Participants will receive a single IV infusion dose of tulisokibart at dose 3 on Day 1.

    Drug: Tulisokibart

  • Placebo comparator
    Placebo IV Infusion

    Participants will receive a single IV infusion dose of placebo on Day 1.

    Drug: Placebo

Interventions

  • SC Injection or IV Infusion

    Also known as: MK-7240

  • DrugPlacebo

    Tulisokibart-matched Placebo SC Injection or IV Infusion

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 99 Days

  2. Number of Participants Who Discontinued the Study Due to AEs

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 99 days

  3. Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last) of Tulisokibart

    Blood samples will be collected to determine the AUC0-last of tulisokibart.

    Time frame: Predose and at designated timepoints (up to 99 days postdose)

  4. Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of Tulisokibart

    Blood samples will be collected to determine the AUC0-inf of tulisokibart.

    Time frame: Predose and at designated timepoints (up to 99 days postdose)

  5. Maximum Concentration (Cmax) of Tulisokibart

    Blood samples will be collected to determine the Cmax of tulisokibart.

    Time frame: Predose and at designated timepoints (up to 99 days postdose)

  6. Time to Maximum Concentration (Tmax) of Tulisokibart

    Blood samples will be collected to determine the Tmax of tulisokibart.

    Time frame: Predose and at designated timepoints (up to 99 days postdose)

  7. Apparent Terminal Half-life (t1/2) of Tulisokibart

    Blood samples will be collected to determine the t1/2 of tulisokibart.

    Time frame: Predose and at designated timepoints (up to 99 days postdose)

  8. Apparent Clearance (CL/F) of Tulisokibart

    Blood samples will be collected to determine the CL/F of tulisokibart.

    Time frame: Predose and at designated timepoints (up to 99 days postdose)

  9. Apparent Volume of Distribution (Vz/F) of Tulisokibart

    Blood samples will be collected to determine the Vz/F of tulisokibart.

    Time frame: Predose and at designated timepoints (up to 99 days postdose)

Secondary outcomes

  1. Absolute Bioavailability Expressed as a Percentage (F%) of SC Tulisokibart

    Blood samples will be collected to determine the F% of tulisokibart.

    Time frame: Predose and at designated timepoints (up to 99 days postdose)

07

Study locations

1 site
  • Peking University Third Hospital (Site 0001)
    Beijing, Beijing 100191, China
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Nov 2024, 4 months.

Of 58 industry-sponsored phase 1 interventional studies under Colitis, Ulcerative, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 18. This study's 4 months is below that.

Counting every sponsor, half of 84 studies reached it within 13 months; a quarter within 8 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2025
First posted
Feb 17, 2025
StartActual
Jun 13, 2024
Primary completionActual
Nov 11, 2024
CompletionActual
Nov 11, 2024
Last update
Feb 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06829225
Responsible party
Sponsor
First posted
Feb 17, 2025
Start date
Jun 13, 2024
Primary completion
Nov 11, 2024
Completion
Nov 11, 2024
Last update
Feb 17, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tulisokibart

Start the discussion